A few studies suspected that PIK3CA mutation is a potential predictive marker in chemotherapy resistance, while the study cohorts were limited and the effect did not focus on stage III CRC patients (24), while patients at stage III with PIK3CA mutation were more likely to have disease recurrence or progression. The gene discussed is PIK3CA; the disease is colorectal carcinoma.